Evidence map›Paper›PMID 33082848›Full record

ArticleEcancermedicalscience2020

Cancer disease progression and death during the COVID-19 pandemic: a multidisciplinary analysis for the Peruvian setting.

Juan Astigueta-Pérez, Milagros Abad-Licham, Carlos Chávez-Chirinos, Luis Beraun-Milla, Alberto Lachos-Dávila, Elizabeth Diaz-Pérez, Karem Portugal-Valdivia, Paul Pilco Castañeda, Isaías Pérez Alférez, Edward Mezones-Holguín

Open access · goldAbstract readEditorial
In one paragraph

Article in Ecancermedicalscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Juan Astigueta-PérezDepartamento de Cirugía Oncológica, Instituto Regional de Enfermedades Neoplásicas Norte, Trujillo 13600, Peru.
Milagros Abad-LichamFacultad de Medicina, Universidad Privada Antenor Orrego, Trujillo 13007, Peru.
Carlos Chávez-ChirinosDepartamento de Cirugía Oncológica, Instituto Regional de Enfermedades Neoplásicas Sur, Arequipa 04000, Peru.
Luis Beraun-MillaDepartamento de Cirugía Oncológica, Instituto Regional de Enfermedades Neoplásicas Centro, Huancayo 12000, Peru.
Alberto Lachos-DávilaDepartamento de Radioterapia, Instituto Nacional de Enfermedades Neoplásicas, Lima 15000, Peru.
Elizabeth Diaz-PérezDepartamento de Especialidades Médicas, Instituto Nacional de Enfermedades Neoplásicas, Lima 15000, Peru.
Karem Portugal-ValdiviaDepartamento de Oncología, Hospital Santa Rosa, Lima 15000, Peru.
Paul Pilco CastañedaCirugía Oncológica, Clínica Delgado, Lima 15000, Peru.
Isaías Pérez AlférezArchivo Regional del Gobierno Regional de Tacna, Universidad Nacional Jorge Basadre, Tacna 23004, Peru.
Edward Mezones-HolguínCentro de Excelencia en Investigaciones Económicas y Sociales en Salud, Universidad San Ignacio de Loyola, Lima 15012, Peru.
Antenor Orrego Private University · PEUniversidad San Ignacio de Loyola · PE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the COVID-19 pandemic began in China in late 2019, infection from the SARS-CoV-2 virus has spread virtually worldwide. This infection has adversely affected several countries; governments have outlined a series of political measures aimed to preserve the health and safety of their populations. In Peru, most actions have prioritised COVID-19 attention, with a subsequent gap in the healthcare facilities needed for other diseases. Cancer, one principal cause of death in the country, is usually diagnosed late. Moreover, in the pandemic context, the prevention and control of cancer have been negatively affected. Therefore, we carried out a multidisciplinary analysis using the Ishikawa diagram to identify the probable factors that contribute to cancer progression and deaths in Peru.

Indexed as

cancerCOVID-19healthcare systemspandemicPeruSARS-COV-2

Identifiers

PMID33082848
PMCPMC7532026
OpenAlexW3084036613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.